HIV Infections
Conditions
Keywords
HIV-infection, viral load, CCR5, viral tropism, HIV-1 infection, Treatment Naive
Brief summary
This study will evaluate the safety, pharmacokinetics and efficacy of the CCR5 antagonist INCB009471 in HIV-1 infected patients who are antiretroviral therapy naïve, or who are not currently on a HAART regimen and have not received any antiretroviral agents for 3 months prior to the Screening visit. Subjects will receive study medication (INCB009471) admnistered orally or placebo once daily with food for 14 days. Clinical safety laboratories, 12-lead electrocardiograms, physical examinations and virologic assessments, including viral load, viral tropism and CD4+ cell count determinations will be performed at the Screening visit and at regularly scheduled visits throughout the study. A blood sample will also be obtained and stored to potentially determine the genotype of the CCR5 receptor. The primary objectives are: 1. Assess the safety and tolerability of 3 doses of INCB009471 or placebo when administered orally, once daily, as monotherapy for 14 days; 2. Determine the pharmacokinetics of 3 doses of INCB009471 or placebo when administered orally, once daily, as monotherapy for 14 days; 3. Evaluate the anti-retroviral activity of 3 doses of INCB009471 or placebo when administered orally, once daily, as monotherapy for 14 days
Interventions
DRUGINCB009471
100mg SR (sustained release) orally once daily
DRUGPlacebo comparator
Orally once daily
Sponsors
Incyte Corporation
Study design
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
Asymptomatic HIV-1 infected individuals that are treatmen naïve (ie less than 2 weeks prior ARV exposure) or treatment experienced subjects who are not currently on HAART and have not received any ARVs for 3 months prior to Screening. * Males between 18 years and 65 years of age, utilizing adequate contraceptive methods. * Post menopausal or surgically sterile females between 18 years and 65 years of age. Women of childbearing potential, utilizing adequate contraceptive methods. * CD4-lymphocyte count \>350 cells/mm3 * HIV-1 RNA copies/ml \> 10,000. * HIV-1 is CCR5 tropic virus only. * CCR5 antagonist treatment naive. * BMI \> 16 to \< 32 kg/m2. * Have no clinically significant findings on screening evaluations, which in the opinion of the Investigator would interfere with the subject's ability to comply with the protocol. * Able to comprehend and willing to sign an Informed Consent Form.
Exclusion criteria
* Current or recent (\<30 days) opportunistic infection. * Presence of CXCR4- or dual-tropic HIV-1 virus at Screening or Baseline assessments. * Subjects with chronic renal insufficiency * Personal history of cardiac diseases. * History or presence of an abnormal ECG. * History of unstable ischemic heart disease or uncontrolled hypertension. * History of malignancy, with the exception of cured basal cell or squamous cell carcinoma of the skin. * Subjects who have received radiation therapy or cytotoxic chemotherapeutic agents and have not recovered from side effects. * Current treatment or treatment within 30 days or 5 half-lives with another investigational medication or current enrollment in another investigational drug protocol. * Subjects with unstable medical condition (s), which , in the opinion of the Investigator would compromise their participation in the trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety and tolerability will be assessed by monitoring adverse experiences. | Baseline, every 1-7 days following the initiation of treatment through Day 28 and then at Day 42 or the early study termination visit. |
Secondary
| Measure | Time frame |
|---|---|
| The virological response to INCB009471 as monotherapy will be assessed by measuring HIV-1 RNA levels by the Roche Amplicor HIV-1 Monitor® Test, v1.5 - Quantitative. | Baseline, Days 4, 7, 10, 14, 16, 20 and 28 or the early termination study visit. |
Countries
United States
Outcome results
None listed